Phase 1 Study of the Combination of Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2014
At a glance
- Drugs Lapatinib (Primary) ; Temozolomide (Primary)
- Indications Advanced breast cancer; Cancer metastases
- Focus Adverse reactions
- Acronyms LAPTEM
- 31 Aug 2018 Biomarkers information updated
- 27 Jun 2011 Planned End Date changed from 1 Jun 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 27 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.